Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer
Launched by UNIVERSITY OF SASKATCHEWAN · Feb 17, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment approach for patients with locally advanced pancreatic cancer, which is a type of cancer that has spread in the pancreas but is not yet metastatic (meaning it hasn't spread to other parts of the body). The trial will explore the effectiveness and safety of combining a treatment called irreversible electroporation (IRE) with chemotherapy. IRE is a novel procedure that uses electrical pulses to destroy cancer cells without harming nearby healthy tissues. The goal is to see if this combination can help patients live longer and have a better quality of life compared to those receiving chemotherapy alone.
To be eligible for the trial, participants must be adults with confirmed locally advanced pancreatic cancer who can receive chemotherapy as determined by their doctors. Unfortunately, those who are pregnant, have metastatic pancreatic cancer, or are dealing with another active cancer (except for certain skin cancers) cannot participate. If accepted into the study, participants will first undergo 12 weeks of chemotherapy, followed by IRE if their cancer has not progressed. They will continue to receive chemotherapy for an additional 12 weeks after the IRE treatment. Throughout the trial, their quality of life will be monitored every three months. This research is important because it aims to find better treatment options for patients with this challenging type of cancer.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients with biopsy-proven locally advanced pancreatic adenocarcinoma who are candidates for combination chemotherapy as determined by treating oncologists.
- Exclusion Criteria:
- • 1. Pregnancy
- • 2. Metastatic pancreatic cancer
- • 3. Another active second primary cancer with the exception of squamous cell carcinoma of the skin or an in situ cancer.
About University Of Saskatchewan
The University of Saskatchewan is a leading research institution dedicated to advancing health sciences through innovative clinical trials and studies. With a commitment to improving patient outcomes, the university leverages its interdisciplinary expertise and state-of-the-art facilities to conduct rigorous and ethically sound research. By fostering collaborations among researchers, healthcare professionals, and industry partners, the University of Saskatchewan aims to translate scientific discoveries into practical applications that enhance healthcare delivery and contribute to the well-being of communities both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Regina, Saskatchewan, Canada
Saskatoon, Saskatchewan, Canada
Patients applied
Trial Officials
Shahid Ahmed, MD, PhD
Principal Investigator
University of Saskatchewan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials